Skip to main content

Suprapubic Catheter (SPT)

A suprapubic catheter (SPC / SPT) is an indwelling urinary catheter placed percutaneously through the anterior abdominal wall directly into the bladder, bypassing the urethra entirely. The AUA / SUFU NLUTD guideline gives a Strong Recommendation (Grade C) that for NLUTD patients requiring chronic indwelling drainage, suprapubic catheterization is preferred over a urethral Foley — anchored on reduced urethral injury, lower CAUTI rates, preserved sexual function, and improved patient comfort.[1][2]

Design and construction​

The SPT is a standard Foley-type catheter (inflatable retention balloon, drainage lumen) placed through a surgically or percutaneously created suprapubic tract rather than per urethra.

  • Sizes 12–24 Fr; ≥ 20 Fr preferred for long-term use to reduce kinking and occlusion.[3]
  • Latex, silicone-coated, and all-silicone materials.
  • Skin exit site 2–3 cm above the pubic symphysis, generally 1–2 cm off midline toward the patient's preferred drainage-bag side.[3]
  • 2-way and 3-way configurations available.

Common devices​

  • Cystofix (B. Braun) — trocar-placed, smaller-caliber (10–12 Fr typical)
  • Bonanno catheter — trocar-placed, pigtail tip
  • Stamey SP catheter — Malecot-tip self-retaining
  • Any Foley catheter can be placed through a created tract and secured with its balloon

Indications​

The SPT is considered when long-term catheterization is needed or urethral catheterization is not feasible / desired.[4]

  • Neurogenic bladder (SCI, MS) when CIC is not feasible — the most common indication.[2][5]
  • Chronic urinary retention refractory to other management.[6]
  • Urethral abnormalities — stricture, false passages, bladder-neck obstruction, urethral fistula.[5]
  • Pelvic-fracture urethral injury (PFUI) — primary suprapubic diversion before delayed posterior urethroplasty. See PFUI.
  • Post-urethral reconstruction — protective diversion during healing.
  • Perineal skin breakdown worsened by urethral catheter.
  • Prostatitis, urethritis, epididymo-orchitis precluding urethral catheterization.[5]
  • Refractory OAB when all other therapies are contraindicated, ineffective, or no longer desired — always with shared decision-making.[1]
  • Patient preference — sexual-function preservation, comfort, avoidance of urethral discomfort.[1]

Contraindications​

  • Nondistended or nonpalpable bladder (insufficient target for safe puncture)
  • Active bladder cancer (risk of tumor seeding along the tract)
  • Abdominal-wall sepsis or infection at the planned site
  • Pregnancy
  • Active anticoagulation / antiplatelet therapy — relative
  • Subcutaneous vascular graft in the suprapubic region
  • Prior pelvic irradiation — relative
  • Prior lower abdominal surgery — relative; bowel adhesions may overlie the bladder[7]

Insertion techniques​

1. Percutaneous trocar (bedside)​

The most common bedside / emergent technique[7][8][9]:

  1. Confirm a distended, palpable bladder (clinically or by ultrasound).
  2. Local anesthesia ~ two fingerbreadths above the pubic symphysis in the midline.
  3. Small skin incision (1–2 cm).
  4. Advance a sharp trocar through the abdominal wall into the bladder.
  5. Remove the obturator; feed a Foley through the trocar sheath.
  6. Inflate the balloon; gentle traction × 5 min for hemostasis; secure to skin.

Average procedure time < 10 min.[9]

2. Percutaneous Seldinger​

Needle puncture under US or fluoroscopic guidance → guidewire → serial dilation → catheter advanced over the wire. Average 25.7 min but allows more precise placement.[10]

3. Cystoscopy-guided​

Cystoscope per urethra visualizes the bladder dome; trocar / needle advanced percutaneously under direct cystoscopic vision. The safest method — used in 98% of insertions in the largest published series (n = 1,000).[11]

4. Open cystostomy​

Reserved for prior pelvic surgery, peritoneal adhesions, or when percutaneous access is unsafe.

5. Nephrostomy balloon and sheath (NBS-SPT)​

Newer minimally invasive technique for initial placement of large-caliber (≥ 20 Fr) catheters under cystoscopic guidance; median operative time 16 min; 100% success at ≥ 20 Fr placement.[3]

Guidance modalities​

The guidance method is the main determinant of bowel-injury risk:[7][11]

  • Ultrasound — BAUS/AUA recommend US whenever possible to identify interposed bowel and confirm a safe trajectory; especially important for bedside/emergency insertion.
  • Cystoscopic — direct real-time visualization of the needle entering the bladder dome; in the 1,000-procedure elective series, cystoscopy- or sound-guided placement gave Clavien ≥IIIb in only 0.6% with zero bowel injuries.
  • Blind / palpation — relies on a palpable distended bladder; still used in emergencies but carries the highest bowel-injury risk (up to ~2.4%, mortality ~1.8%) and should be avoided after prior abdominal surgery.

Hydrodissection to displace bowel​

When ultrasound shows bowel overlying the anterior bladder wall and obscuring a safe route — typically in a patient unfit for the general anesthesia an open approach would need — hydrodissection can open a window (Chan & Speirs):[12]

  1. Fill the bladder via the urethral catheter and visualize with ultrasound.
  2. Under US guidance, insert a 22-G needle (syringe of 30 mL: 10 mL 1% lidocaine + 20 mL sterile water) into the space between the pubic symphysis and the overlying bowel.
  3. Inject to hydrodissect the bowel away from the bladder, opening a safe corridor.
  4. Pass an 18-G needle into the bladder through the corridor and place the SPC by Seldinger technique.

Reported with successful placement, no bowel or other injury, and no complications at 6 months — case-level evidence, but the bowel-displacement principle is well established in interventional radiology. (For the agent/technique of hydrodissection generally, see Hydrodissection.)

Trocar vs Seldinger — head-to-head​

The only direct comparison (Roberts 2020; 125 IR image-guided cystostomies) found both 100% technically successful with rare major complications, trading speed against occlusion:[10]

OutcomeTrocar (n=60)Seldinger (n=65)p
Procedure time12.4 min25.7 min.001
Catheter size13.1 Fr13.9 Fr.044
Midazolam dose1.2 mg1.9 mg.003
Radiation20.2 mGy100.7 mGy.001
Catheter occlusion41.7%16.9%.003
Bladder spasm1.7%13.8%.018

Trocar is faster, with less sedation and radiation; the higher occlusion rate was attributed to a catheter–tract size mismatch (smaller catheters threaded through the sheath). Seldinger gives more controlled, stepwise access (favored for difficult anatomy and US guidance), and newer Seldinger kits are credited with part of the national fall in bowel-injury rates — 2.4% historically to ~0.09% in contemporary UK practice.[24]

Advantages over urethral Foley​

AdvantageDetail
No urethral traumaEliminates urethral erosion, stricture, "traumatic hypospadias"[1][2]
Lower CAUTI ratesLower density of gram-negative organisms on abdominal skin vs periurethral area[3][4]
ComfortLess catheter-associated pain[3]
Preserved sexual functionNo interference with sexual activity[2]
Voiding trial without removalClamp the SPT and attempt normal voiding[1]
Fewer ED visits35% vs 68% in elderly transitioning urethral → suprapubic[13]
Fewer obstructionsSignificantly fewer than urethral catheters[13]
Reduced antibiotic resistanceLower prevalence of resistant organisms[5]

A within-subject study (Perez 2025, Neurourol Urodyn) of 37 elderly patients transitioning from urethral to suprapubic catheters showed CAUTI rates fell from 86% → 38% (p < 0.001).[13]

A 3-NHS-institution audit reported a 10% intraoperative complication rate including anesthesia-related events, positioning failures, bowel injury / perforation, and catheter malposition / expulsion.[14] The largest published series (Hobbs 2022, n = 1,000 elective procedures) reported major complications (Clavien-Dindo ≥ IIIb) in only 0.6%, return to OR in 0.4%, and no bowel injuries.[11]

Bowel injury risk with blind percutaneous insertion is up to 2.4% with mortality ~ 1.8%.[7] This is substantially mitigated by ultrasound or cystoscopic guidance.

Long-term complications​

A 10-yr longitudinal study found 59.9% experienced long-term complications, but Clavien ≥ III in only 23%.[6]

  • Catheter obstruction / encrustation — most common (28.8% in one series).[10]
  • CAUTI — bacteriuria is universal after 30 days; only symptomatic infections should be treated.[15]
  • Bladder-stone formation — higher than with external devices or CIC.[5]
  • Granulation tissue at the cystostomy site — bleeding, stricture.[1]
  • Catheter-site erosion / leakage — including urethral leakage despite suprapubic drainage.[5]
  • Tract loss during routine changes — community-care education gap flagged in Hobbs 2022.[11]
  • Bladder spasms — managed with anticholinergics, β3 agonists, or intradetrusor onabotulinumtoxinA.
  • Altered body image — significant psychosocial consideration.

Bladder-cancer risk — long-term indwelling caveat​

Long-term indwelling catheterization (urethral or suprapubic) is associated with significantly increased risk of bladder cancer, particularly squamous cell carcinoma.[16][17][18]

  • Tseng 2025 Taiwanese population study (n = 72,971 chronic indwelling catheters): 5.16-fold higher bladder-cancer risk vs controls (213.29 vs 40.4 per 100,000 person-yr).[16]
  • Hird 2021 Ontario population study (n = 36,903): chronic catheterization HR 4.80 for bladder cancer and HR 8.68 for bladder-cancer–specific mortality. Risk highest beyond 2.9 years.[17]
  • In SCI specifically, indwelling catheter use confers RR 4.9 vs non-indwelling methods.[19]
  • Histology (Delnay 1999): chronic-catheter SCI patients (> 8.5 yr) had 8.2% malignancy (predominantly SCC) and 23% premalignant changes (keratinizing squamous metaplasia, cystitis glandularis).[20]
  • Periodic urine cytology and cystoscopy may be indicated for catheters > 10 years, though specific screening protocols remain evidence-light.[21]

Long-term management and replacement​

General care: closed drainage system, bag below bladder level, hydration ~30 mL/kg/day, treat constipation; do not screen for or treat asymptomatic bacteriuria (universal in chronic-indwelling patients).[15]

First exchange — timing and technique​

The first exchange is the highest-risk change because the cystostomy tract has not yet epithelialized. Perform it no earlier than 4–6 weeks; per UK minimum standards, keep initial insertion (and ideally the first change) in secondary/tertiary care, releasing routine community changes only once the tract is established.[27][11] Larger initial caliber appears to help — in the NBS-SPT (≥20 Fr) series the first clinic exchange succeeded in 95%, with only 2/65 needing replacement under anesthesia.[3]

Technique to avoid tract loss / false passage:

  • Passive balloon deflation (let it empty by gravity, not active aspiration) avoids the balloon-surface ridging that causes pain and mucosal trauma on withdrawal.[4]
  • Guidewire-assisted (Seldinger) exchange for early or difficult tracts — pass a wire through the existing catheter lumen before removal and railroad the new catheter over it; the Van Buren sound technique at initial placement builds the same wire-guided safety in for early exchanges.[25]
  • Insert the new catheter to the same depth (often ~8 cm from skin); scale-marked catheters help.[26]
  • Confirm intravesical position by aspirating urine — if none returns, do not force; use ultrasound or wire-guided reinsertion.
  • The tract can close within hours if a catheter is dislodged in the early weeks — replace promptly (a urethral Foley railroaded through the tract is a temporizing measure).

A multifunctional catheter (scale markings + modified drainage holes) reduced both cystospasm and occlusion versus conventional balloon catheters in an RCT.[26]

Replacement interval — guideline divergence​

No consensus exists. Most urologic bodies suggest ~4-weekly changes (maximum 12 weeks); CDC/IDSA find insufficient data and advise changing for infection or obstruction; the EAU times changes to anticipate the individual's blockage pattern; NICE favors individualization, flagging recurrent blockage before 6 weeks as a red flag for bladder stones or encrustation.[22][4]

Ancillary treatment​

In the Willging 2025 longitudinal cohort, 46% of long-term SPT patients required ancillary lower-tract treatments (anticholinergics, intradetrusor onabotulinumtoxinA). The absence of ancillary treatments was strongly associated with SPT discontinuation (OR 56.8), suggesting proactive treatment increases SPT longevity.[6]

SPT in spinal cord injury / NLUTD​

The ACS Best Practices Guidelines for Spine Injury[23] and the AUA / SUFU NLUTD Guideline[2]:

  • CIC is the preferred bladder-management method once precise output measurement is no longer required.
  • When chronic indwelling drainage is needed, suprapubic is recommended over urethral — avoids irreversible urethral injury, periurethral abscess, epididymitis.
  • AUA / SUFU Strong Recommendation (Grade C): for NLUTD patients on chronic indwelling drainage, recommend suprapubic over urethral catheterization.[2]
  • Consider general or spinal anesthesia for SPT placement in SCI patients to manage autonomic dysreflexia during bladder distension.
  • Ongoing urologic follow-up including urodynamics is required.

Comparison: urethral Foley vs SPT vs CIC​

FeatureUrethral FoleySuprapubic CatheterCIC
InsertionBedsideSurgical / percutaneous procedurePatient self-performed
Urethral traumaHigh (erosion, stricture)NoneLow
CAUTI riskHighestLower than urethralLowest
Bladder-stone riskModerateHigherLowest
Sexual function impactSignificant interferenceMinimalNone
ComfortLowestHigherHighest
Bladder-cancer risk (long-term)ElevatedElevatedLower
Patient independenceNoneNoneHigh
Preferred for chronic useNo (AUA recommends against)Yes (AUA Strong Recommendation)Yes (preferred overall when feasible)

When to refer to urology​

  • Initial SPT placement (procedural expertise required)
  • Recurrent CAUTIs or catheter-related complications
  • Suspected urethral injury or tract loss
  • Long-term catheterization strategy decisions
  • Bladder-cancer surveillance for catheters > 10 years
  • Need for ancillary treatments (anticholinergics, intradetrusor BoNT, augmentation)
  • Consideration of definitive urinary diversion

See Also​

Foley Catheter · Council Tip Catheter · Coudé Catheter · Intermittent Catheter · PFUI · Urinary Diversion

References​

1. Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. 2024;212(1):11-20. doi:10.1097/JU.0000000000003985

2. Ginsberg DA, Boone TB, Cameron AP, et al. The AUA/SUFU guideline on adult neurogenic lower urinary tract dysfunction: treatment and follow-up. J Urol. 2021;206(5):1106-1113. doi:10.1097/JU.0000000000002239

3. Flynn KJ, Schlaepfer CH, Khawaja F, Erickson BA. Nephrostomy balloon and sheath suprapubic tube placement — a minimally invasive approach to large caliber suprapubic tube placement. Urology. 2022;164:e302. doi:10.1016/j.urology.2022.03.013

4. Fletke KJ, Jeong DH, Herrera AV. Urinary catheter management. Am Fam Physician. 2024;110(3):251-258.

5. Edokpolo LU, Foster HE. Suprapubic cystostomy for neurogenic bladder using Lowsley retractor method: a procedure revisited. Urology. 2011;78(5):1196-1198. doi:10.1016/j.urology.2011.07.1393

6. Willging AM, Khawaja F, Erickson BA. Suprapubic catheter drainage for the definitive, long-term management of lower urinary tract dysfunction: utilization patterns and longitudinal outcomes. Urology. 2025. doi:10.1016/j.urology.2025.10.002

7. Jacob P, Rai BP, Todd AW. Suprapubic catheter insertion using an ultrasound-guided technique and literature review. BJU Int. 2012;110(6):779-784. doi:10.1111/j.1464-410X.2011.10882.x

8. Kidd EA, Stewart F, Kassis NC, Hom E, Omar MI. Urethral (indwelling or intermittent) or suprapubic routes for short-term catheterisation in hospitalised adults. Cochrane Database Syst Rev. 2015;(12):CD004203. doi:10.1002/14651858.CD004203.pub3

9. Goyal NK, Goel A, Sankhwar SN. Safe percutaneous suprapubic catheterisation. Ann R Coll Surg Engl. 2012;94(8):597-600. doi:10.1308/003588412X13373405385412

10. Roberts DG, Patel RB, Genshaft SJ, et al. Interventional radiology image-guided suprapubic cystostomy using trocar versus Seldinger technique: a comparative analysis of outcomes and complications. Urology. 2020;142:207-212. doi:10.1016/j.urology.2020.05.015

11. Hobbs C, Howles S, Derry F, Reynard J. Suprapubic catheterisation: a study of 1000 elective procedures. BJU Int. 2022;129(6):760-767. doi:10.1111/bju.15727

12. Chan KKC, Speirs A. Novel use of hydrodissection for the insertion of suprapubic catheter under ultrasound guidance. Urology. 2020;136:263-265. doi:10.1016/j.urology.2019.09.041

13. Perez D, Shapiro DS, Bohm D, et al. Comparative outcomes of indwelling urethral versus suprapubic catheters in elderly patients: a retrospective within-subject study. Neurourol Urodyn. 2025. doi:10.1002/nau.70133

14. Cravens DD, Zweig S. Urinary catheter management. Am Fam Physician. 2000;61(2):369-376.

15. Niël-Weise BS, van den Broek PJ, da Silva EM, Silva LA. Urinary catheter policies for long-term bladder drainage. Cochrane Database Syst Rev. 2012;(8):CD004201. doi:10.1002/14651858.CD004201.pub3

16. Tseng WH, Lee CH, Lin RJ, et al. Risk of bladder cancer in patients with chronic indwelling catheters: a real-world data analysis. J Cancer. 2025;16(11):3464-3472. doi:10.7150/jca.114223

17. Hird AE, Saskin R, Liu Y, et al. Association between chronic bladder catheterisation and bladder cancer incidence and mortality: a population-based retrospective cohort study in Ontario, Canada. BMJ Open. 2021;11(9):e050728. doi:10.1136/bmjopen-2021-050728

18. Ho CH, Sung KC, Lim SW, et al. Chronic indwelling urinary catheter increase the risk of bladder cancer, even in patients without spinal cord injury. Medicine (Baltimore). 2015;94(43):e1736. doi:10.1097/MD.0000000000001736

19. Groah SL, Weitzenkamp DA, Lammertse DP, et al. Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil. 2002;83(3):346-351. doi:10.1053/apmr.2002.29653

20. Delnay KM, Stonehill WH, Goldman H, Jukkola AF, Dmochowski RR. Bladder histological changes associated with chronic indwelling urinary catheter. J Urol. 1999;161(4):1106-1109.

21. Welk B, McIntyre A, Teasell R, Potter P, Loh E. Bladder cancer in individuals with spinal cord injuries. Spinal Cord. 2013;51(7):516-521. doi:10.1038/sc.2013.33

22. Cooper FP, Alexander CE, Sinha S, Omar MI. Policies for replacing long-term indwelling urinary catheters in adults. Cochrane Database Syst Rev. 2016;7:CD011115. doi:10.1002/14651858.CD011115.pub2

23. Schroeder GD, Vaccaro AR, Welch WC, et al. Best practices guidelines: spine injury. American College of Surgeons; 2022.

24. Hall S, Ahmed S, Reid S, et al. A national UK audit of suprapubic catheter insertion practice and rate of bowel injury with comparison to a systematic review and meta-analysis of available research. Neurourol Urodyn. 2019;38(8):2194-2199. doi:10.1002/nau.24114

25. Wyner LM. Easy suprapubic tube placement using a Van Buren sound. Urology. 2018;114:245. doi:10.1016/j.urology.2018.01.006

26. Dong HJ, Lu Y, Zhang NZ, et al. Clinical evaluation of the multifunctional suprapubic catheter in patients requiring permanent suprapubic cystostomy: a prospective randomised trial in a single centre. J Clin Nurs. 2019;28(13-14):2499-2505. doi:10.1111/jocn.14208

27. Rantell A, Dolan L, Bonner L, et al. Minimum standards for continence care in the UK. Neurourol Urodyn. 2016;35(3):400-406. doi:10.1002/nau.22717